Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Background: A recently registered device containing 80 mg of adalimumab (ADA) allows an alternative dose escalation regimen with ADA 80 mg every other week (EOW) given as a single subcutaneous injection instead of 40 mg every week. The ADASCAL study evaluated the preferences and satisfaction of infl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Carlos Taxonera, María Pilar Martínez-Montiel, Manuel Barreiro-de-Acosta, Isabel Vera, Rufo Lorente, Pablo Vega, María Teresa Diz-Lois, Ana María Fuentes Coronel, José Lázaro Pérez Calle, Begoña Casis, Rocío Ferreiro-Iglesias, Marta Calvo, David Olivares, Cristina Alba
Formato: article
Lenguaje:EN
Publicado: SAGE Publishing 2021
Materias:
Diseases of the digestive system. Gastroenterology
RC799-869
Acceso en línea:https://doaj.org/article/9028789dcdd649f38c8d7504b1e8a2d2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/9028789dcdd649f38c8d7504b1e8a2d2

Ejemplares similares